Hemlibra
Named-patient access overview. Hemlibra is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Hemlibra (emicizumab-kxwh) is Roche's bispecific antibody for hemophilia A prophylaxis. It bridges factor IXa and factor X to restore the function missing factor VIII would otherwise provide, and it works in patients with or without factor VIII inhibitors. It received FDA approval in 2017 for inhibitor patients and in 2018 for the broader hemophilia A population. For Saudi Arabia hemophilia A families weighing emicizumab, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Hemlibra
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Hemlibra is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Hemlibra in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Hemlibra
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.